| Quarterly Financials | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 203 | 223 | 234 | 250 | 263 | 277 |
| Expenses | 153 | 168 | 180 | 182 | 199 | 215 |
| EBITDA | 50 | 55 | 54 | 68 | 64 | 62 |
| Operating Profit % | 22 % | 23 % | 21 % | 26 % | 23 % | 19 % |
| Depreciation | 18 | 19 | 20 | 23 | 22 | 26 |
| Interest | 5 | 6 | 6 | 45 | 6 | 3 |
| Profit Before Tax | 26 | 30 | 29 | -1 | 36 | 33 |
| Tax | 6 | 5 | 5 | 9 | 4 | 3 |
| Net Profit | 20 | 25 | 24 | -10 | 32 | 30 |
| EPS in ₹ | 2.47 | 3.05 | 13.10 | -1.12 | 3.43 | 3.03 |
Nephrocare Health Services
Nephrocare Health Services
723.35
-13.65
(-1.85%)
Market Cap
7,258.15 Cr
PE Ratio
96.33
Volume
2,61,481.00
Day High - Low
745.85 - 713.20
52W High-Low
769.75 - 446.00
There are new updates from the company1 day ago
View
Key Fundamentals
Market Cap
7,258.15 Cr
EPS
8.48
PE Ratio
96.33
PB Ratio
6.63
Book Value
111.27
EBITDA
223.87
Dividend Yield
0.00 %
Industry
Healthcare Services Sector
Healthcare Service Provider Return on Equity
11.49
Debt to Equity
0.53
Analyst Rating and Forecast
- By Refinitiv from3 analysts
Actual
Company News
View All News
Nephrocare cancels investor meetings
1 day ago
1 day agoNephrocare Health Services Ltd cancelled analyst and institutional investor meetings scheduled for June 18-19, 2026, due to unavoidable exigencies.
Bessemer Venture Partners Trust confirmed no encumbrance was created on Nephrocare Health Services Limited shares in FY26.
Nephrocare Unit Signs Asset Transfer Deal With Inocentes DialysisJun 04, 2026
A unit of Nephrocare Health Services has signed an asset transfer agreement with Inocentes Dialysis Clinic, marking a notable corporate development for the company.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,662.90 | #1 27,862.72 | 54.27 | #1 2,762.90 | 8.15 | #1 510 | -14.98 | 64.21 | |
1,305.60 | 13,434.20 | 77.29 | 814.20 | 16.36 | 182 | 37.25 | 56.40 | |
542.50 | 11,247.53 | 59.19 | 1,645.85 | 22.25 | 185 | 74.66 | 57.09 | |
534.40 | 8,505.79 | 52.10 | 846.00 | 20.48 | 163 | #1 125.46 | 64.64 | |
723.35 | #5 7,258.15 | #9 96.33 | #4 998.85 | #2 29.74 | #7 62 | #7 22.09 | 63.30 | |
533.65 | 1,731.09 | #1 17.11 | 772.77 | 4.05 | 106 | 101.45 | 38.22 | |
694.00 | 1,356.26 | 20.54 | 498.18 | #1 237.06 | 69 | 65.45 | 70.96 | |
259.65 | 1,352.28 | 44.25 | 310.41 | 21.30 | 34 | -13.89 | 33.19 | |
1,201.10 | 1,030.86 | 17.24 | 141.92 | 27.17 | 61 | 22.50 | 46.91 | |
317.65 | 1,010.46 | -688.89 | 1,319.27 | 12.68 | -3 | -173.86 | 62.90 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
29.74 %
Net Income Growth
-7.73 %
Cash Flow Change
87.26 %
ROE
35.34 %
ROCE
60.40 %
EBITDA Margin (Avg.)
-6.81 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 428 | 571 | 666 | 806 | 997 | 1,471 |
| Fixed Assets | 192 | 205 | 239 | 356 | 396 | 436 |
| Current Assets | 178 | 285 | 324 | 390 | 545 | 839 |
| Capital Work in Progress | 2 | 43 | 34 | 1 | 6 | 6 |
| Investments | 0 | 0 | 0 | 0 | 51 | 33 |
| Other Assets | 234 | 322 | 393 | 450 | 544 | 0 |
| Total Equity & Liabilities | 428 | 571 | 666 | 806 | 997 | 1,471 |
| Current Liabilities | 94 | 94 | 175 | 243 | 284 | 299 |
| Non Current Liabilities | 75 | 81 | 103 | 150 | 129 | 55 |
| Total Equity | 259 | 396 | 389 | 414 | 584 | 1,117 |
| Reserve & Surplus | 245 | 387 | 384 | 409 | 579 | 1,096 |
| Share Capital | 4 | 5 | 5 | 2 | 2 | 20 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 5 | 6 | -5 | 47 | 65 |
| Investing Activities | -62 | -130 | -76 | -52 | -125 |
| Operating Activities | 32 | 14 | 11 | 72 | 135 |
| Financing Activities | 36 | 121 | 60 | 27 | 54 |
Share Holding
| % Holding | Jul 2025 | Dec 2025 | Mar 2026 |
| Promoter | 79.05 % | 63.85 % | 63.85 % |
| FIIs | 0.00 % | 9.30 % | 9.94 % |
| DIIs | 0.00 % | 8.10 % | 8.65 % |
| Government | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 5.92 % | 5.08 % |
| Others | 20.94 % | 12.82 % | 12.48 % |
| No of Share Holders | 65 | 36 | 43,409 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 10 Feb 2026 |  Quarterly Result Announcement | NA | 10 Feb 2026 | 512.90 | 527.50 |
| 19 May 2026 | Quarterly Result Announcement | NA | 19 May 2026 | 529.25 | 642.10 |
Announcements
Cancellation Of Scheduled Analyst / Institutional Investor Meetings1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJun 04, 2026
Jun 04, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2026
May 27, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2026
May 27, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2026
May 27, 2026Announcement under Regulation 30 (LODR)-AcquisitionMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2026
May 22, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2026
May 20, 2026Re-Appointment Of Internal AuditorMay 19, 2026
May 19, 2026Issuance Of Corporate GuaranteeMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2026
May 19, 2026Board Meeting Outcome for Outcome Of The Board Meeting Held On May 19 2026May 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsMay 12, 2026
May 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 04, 2026
May 04, 2026Board Meeting Intimation for Intimation Of Board Meeting For Considering Audited Financial Results Of The Company.May 04, 2026
May 04, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2026
Apr 10, 2026Announcement under Regulation 30 (LODR)-Change in ManagementApr 03, 2026
Apr 03, 2026Announcement Under Regulation 30 (LODR)- Disclosure Of Litigation Filed By The CompanyApr 02, 2026
Apr 02, 2026Closure of Trading WindowMar 25, 2026
Mar 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 16, 2026
Mar 16, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2026
Feb 19, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2026
Feb 18, 2026Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2026
Feb 10, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 10, 2026
Feb 10, 2026Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2026
Feb 10, 2026Board Meeting Outcome for Outcome Of The Board Meeting Held On February 10 2026Feb 10, 2026
Feb 10, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 07, 2026
Feb 07, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 30, 2026
Jan 30, 2026Board Meeting Intimation for Considering And Approving Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended 31St December 2025.Jan 30, 2026
Jan 30, 2026Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJan 27, 2026
Jan 27, 2026Issuance Of Corporate Guarantee For And On Behalf Of Nephrocare Health Care Services Philippines Inc. Philippines Step-Down Wholly-Owned Subsidiary Not Exceeding USD 6.00 Million. Jan 15, 2026
Jan 15, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 15, 2026
Jan 15, 2026We Would Like To Inform That Pursuant To The Listing Of Equity Shares Of The Company On The Recognized Stock Exchanges Namely BSE Limited And National Stock Exchange Of India Limited The CIN Of The Company Has Been Changed From U85100TG2009PLC066359 To L8Jan 15, 2026
Jan 15, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 08, 2026
Jan 08, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotJan 07, 2026
Jan 07, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotJan 07, 2026
Jan 07, 2026Announcement under Regulation 30 (LODR)-Change in ManagementJan 05, 2026
Jan 05, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Dec 23, 2025
Dec 23, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.07% | 0 | 0.00% | 0.01% | |
Bandhan Small Cap Fund Direct-Growth | 0.00% | 0 | 0.00% | 0.00% | |
 Baroda BNP Paribas Health and Wellness Fund Direct-Growth | 1.65% | 0 | 0.15% | 0.17% | |
Baroda BNP Paribas Small Cap Fund Direct-Growth | 1.47% | 0 | 0.00% | 0.15% | |
 DSP Healthcare Fund Direct-Growth | 1.15% | 0 | 0.00% | 0.08% | |
 Edelweiss Aggressive Hybrid Fund Direct-Growth | 0.00% | 0 | 0.00% | 0.00% | |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth | 0.00% | 0 | 0.00% | -0.42% | |
ICICI Prudential Retirement Fund - Hybrid Aggressive Plan Direct-Growth | 1.01% | 0 | 0.00% | 0.01% | |
 SBI Children's Fund - Investment Plan Direct-Growth | 0.37% | 0 | 0.00% | 0.03% | |
SBI Healthcare Opportunities Fund Direct Plan-Growth | 1.05% | 0 | 0.00% | 0.07% | |
 Union Value Fund Direct-Growth | 0.92% | 0 | 0.00% | 0.10% | |
 WhiteOak Capital Pharma and Healthcare Fund Direct-Growth | 0.60% | 0 | 0.00% | 0.60% |
Technical Indicators
RSI(14)
Neutral 67.22
ATR(14)
Less Volatile 36.04
STOCH(9,6)
Neutral 78.87
STOCH RSI(14)
Neutral 56.35
MACD(12,26)
Bullish 5.66
ADX(14)
Strong Trend 39.25
UO(9)
Bearish 57.49
ROC(12)
Uptrend And Accelerating 15.77
WillR(14)
Overbought -18.85
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
